Benefits
Recurrent UTI prevention in women (FDA-acknowledged)
In sexually active women with recurrent UTIs, 500 mg/day Pacran for 6 months reduced the proportion with at least one UTI from 25.8% (placebo) to 10.8% (Pacran), a 58% relative reduction. The FDA cited this evidence when granting the 2020 qualified health claim for cranberry supplements and UTI risk reduction.
Culture-confirmed UTI reduction
In women with a recurrent UTI history, 500 mg/day Pacran vs placebo over 6 months, with UTIs confirmed by urine culture rather than self-report, significantly reduced the incidence of culture-confirmed UTIs and improved related UTI markers. The culture-based primary outcome eliminates self-report bias.
Anti-adhesion mechanism (well-characterized)
Cranberry A-type PACs prevent E. coli P-fimbriae from adhering to uroepithelial cells — a well-characterized mechanism distinct from antibiotic killing. Bacteria that cannot adhere are washed out with normal urination rather than colonizing and causing infection. Mechanism doesn't promote antibiotic resistance and is complementary to standard treatment.
Whole-fruit vs PAC-extract approach
Pacran uses the whole cranberry fruit (not just PAC-isolated extract). This delivers the natural matrix of bioactives — PACs plus anthocyanins, organic acids (benzoic, quinic), and phenolics. Some research suggests the whole-fruit synergy may outperform isolated PACs at equivalent PAC doses, though this is debated; the PACCANN trial protocol specifically tests this.
Safety in long-term use
Daily use over 6 months was well tolerated, with no effects on clinical chemistry, hematology, or urinalysis parameters vs placebo. Suitable for chronic preventive use in women with recurrent UTI history, where the alternative, chronic low-dose antibiotic prophylaxis, drives antibiotic resistance.
Convenient single capsule daily
Unlike cranberry juice (which requires large daily volumes and often contains added sugars), Pacran delivers the clinical PAC dose in one small capsule daily. Significant adherence advantage for a 6-month preventive regimen.
Mechanism of action
A-type proanthocyanidin anti-adhesion
Cranberry contains both A-type and B-type proanthocyanidins. The A-type linkages are structurally unique to cranberry and are the active anti-adhesion compounds — they bind to E. coli P-fimbriae and prevent attachment to mannose receptors on uroepithelial cells. B-type PACs (common in many plants) lack this specific anti-adhesion activity.
Reduced biofilm formation
PACs may interfere with E. coli biofilm formation on bladder walls. Established biofilms are difficult to clear and contribute to recurrent infections; preventing initial adhesion is key to preventing biofilm establishment.
Acidification (modest contribution)
Cranberry's organic acids (benzoic, quinic, hippuric) historically were thought to acidify urine and inhibit bacterial growth. Modern research indicates this is a minor contributor — the anti-adhesion effect of PACs appears far more important than pH effects.
Hippuric acid antimicrobial effect
Cranberry quinic acid is metabolized to hippuric acid, which has weak antimicrobial activity in urine. Considered a minor mechanism contributor rather than primary action.
Clinical trials
Randomized, double-blind, placebo-controlled trial in 176 sexually active women with history of recurrent UTI (≥2 symptomatic UTIs in previous 12 months). Intervention: 500 mg/day Pacran or placebo for 6 months.
Clinical population described in trial publication.
Randomized, double-blind, placebo-controlled trial in 176 sexually active women with history of recurrent UTI (≥2 symptomatic UTIs in previous 12 months). Intervention: 500 mg/day Pacran or placebo for 6 months. Outcome: 10.8% in Pacran group experienced at least one UTI vs 25.8% in placebo group (p=0.04); 58% relative risk reduction. Time-to-first-UTI also significantly longer in Pacran group. Cited by FDA in 2020 qualified health claim.
Multicenter 6-month randomized double-blind placebo-controlled trial in 150 healthy women with recurrent UTI.
150 healthy women with recurrent UTI
Multicenter 6-month randomized double-blind placebo-controlled trial in 150 healthy women with recurrent UTI. Primary outcome: culture-confirmed UTIs (>10⁸ CFU/L) rather than self-reported UTIs — eliminating self-report bias. Result: significantly reduced incidence of culture-confirmed UTI in Pacran group vs placebo, with improvements on related UTI markers. Most rigorous Pacran trial to date. Published in American Journal of Clinical.